Janssen's migraine drug wins expanded FDA approval

03/31/2014 | Healio (free registration)

Janssen Pharmaceuticals obtained the FDA's approval to market Topamax, or topiramate, for the prevention of migraine in adolescents 12 to 17. Topamax is the first FDA-approved drug for this indication in this age group. The drug was previously approved for treatment of seizure and migraine prevention in adults.

View Full Article in:

Healio (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY